PHILADELPHIA, Oct. 6, 2008 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (Amex:HEB) today announced that it has engaged The Sage Group to assist Hemispherx to identify, select, negotiate, and close a corporate partnership for the commercialization of Hemispherx's Ampligen(r) to treat Chronic Fatigue Syndrome (CFS). The U.S. Food and Drug Administration (FDA) notified Hemispherx that it accepted for review the New Drug Application (NDA) for Ampligen(r) to treat CFS as of July 8, 2008. Pursuant to the Prescription Drug User Fee Act (PDUFA) guidelines, Hemispherx expects that the FDA will complete its review and provide an action letter to the company with respect to the NDA by February 25, 2009. Hemispherx has been approached by potential partners and has engaged The Sage Group to assist Hemispherx in the management of this endeavor to achieve an optimal result for shareholders.
